North East and North Cumbria
ICS Formulary
ICS Formulary
6 Endocrine system
06-06-02 Strontium renelate
Links
CD&TV APC Information sheet to support prescribing and monitoring of Denosumab (Prolia®- MHRA Drug Safety Update (Dec 2014): Bisphosphonates: atypical femoral fractures
- MHRA Drug Safety Update (Dec 2014): Bisphosphonates: osteonecrosis of the jaw
- MHRA Drug Safety Update (Dec 2014: Bisphosphonates: atrial fibrillation
- MHRA Drug Safety Update (Dec 2015): Bisphosphonates: very rare reports of osteonecrosis of the external auditory canal
- MHRA Drug Safety Updates: Denosumab
- MHRA Drug Safety Updates: Denosumab
- MHRA Drug Safety Updates: Denosumab
- NICE HST 8: Burosumab for treating X-linked hypophosphataemia in children and young people
- NICE TA160: Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women
- NICE TA161: Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women
- NICE TA204: Osteoporotic fractures - denosumab
- NICE TA265: Bone metastases from solid tumours - denosumab: guidance
- NICE TA464 Bisphosphonates for treating osteoporosis
- NICE TA464 Bisphosphonates for treating osteoporosis
- NICE TA464 Bisphosphonates for treating osteoporosis
- NICE TA464 Bisphosphonates for treating osteoporosis
- NICE TA791: Romosozumab for treating severe osteoporosis
North East and North Cumbria Integrated Care System Guideline for the management of osteoporosis in primary care- North of Tyne, Gateshead and North Cumbria: DENOSUMAB (Prolia®) 60mg sc twice yearly for osteoporosis Information for Treatment of Adults in Primary Care
- NTAG Endocrine System Recommendations